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Summary: Glucose is the major substrate that sustains normal
brain function. When the brain glucose concentration ap-
proaches zero, glucose transport across the blood–brain barrier
becomes rate limiting for metabolism during, for example, in-
creased metabolic activity and hypoglycemia. Steady-state
brain glucose concentrations in -chloralose anesthetized rats
were measured noninvasively as a function of plasma glucose.
The relation between brain and plasma glucose was linear at 4.5
to 30 mmol/L plasma glucose, which is consistent with the
reversible Michaelis–Menten model. When the model was fit-
ted to the brain glucose measurements, the apparent Michaelis-
Menten constant, Kt, was 3.3 ± 1.0 mmol/L, and the ratio of the
maximal transport rate relative to CMRglc, Tmax/CMRglc, was
2.7 ± 0.1. This Kt is comparable to the authors’ previous human
data, suggesting that glucose transport kinetics in humans and
rats are similar. Cerebral blood flow (CBF) was simultaneously
assessed and constant above 2 mmol/L plasma glucose at 73 ±
6 mL 100 g−1 min−1. Extrapolation of the reversible Michaelis–
Menten model to hypoglycemia correctly predicted the plasma
glucose concentration (2.1 ± 0.6 mmol/L) at which brain glu-
cose concentrations approached zero. At this point, CBF in-
creased sharply by 57% ± 22%, suggesting that brain glucose
concentration is the signal that triggers defense mechanisms
aimed at improving glucose delivery to the brain during hypo-
glycemia. Key Words: Brain—Cerebral blood flow—Glucose
transport—Hypoglycemia—In vivo—NMR.
A supply of glucose is crucial to meet cerebral energy
demands because the brain relies almost exclusively on
glucose for sustained adenosine triphosphate (ATP) gen-
eration (Hawkins et al., 1983; McIlwain and Bachelard,
1985). Glucose enters cells through facilitated diffusion
mediated by specific transporters (Crone, 1965). Glucose
transport across the blood–brain barrier becomes the
rate-limiting step in the regulation of brain function
when brain glucose concentrations approach zero, for
example, during hypoglycemia (Lewis et al., 1974; Par-
dridge, 1984). To understand the role of brain glucose in
the regulation of brain energy metabolism, quantitative
measurements of glucose transport are important. The
knowledge of the mechanism of brain glucose transport
and brain glucose concentrations also is important in the
interpretation of tracer studies using radiolabeled glucose
or glucose analogs (Betz et al., 1976; Blomqvist et al.,
1991; Brooks et al., 1986; Feinendegen et al., 1986;
Gjedde and Diemer, 1983; Gutniak et al., 1990).
Traditionally, glucose transport has been described
based on the standard Michaelis–Menten kinetics, which
assumes unidirectional product formation. The standard
model also predicts that an upper limit exists for the
brain glucose concentration at saturating plasma glucose
concentrations. It is a basic assumption of standard Mi-
chaelis–Menten kinetics that the product formation does
not result in substantial reverse flux, that is, binding of
the product (transmembrane glucose) with the enzyme
(glucose transporter). This condition can be achieved in
vitro by measuring the initial rate of product formation
right after combining enzyme and substrate in the solu-
tion. However, in vivo it is difficult to measure the for-
mation of brain glucose content from zero without
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interfering with brain function and metabolism, which
itself can affect brain glucose content. The standard
Michaelis–Menten formulation is expected to be valid
when the transmembrane glucose concentration is low
compared with the Kt of glucose transport. However, in
the literature, brain glucose concentrations approached
and exceeded reported values of the Michaelis–Menten
constant (Kt) at high plasma glucose concentrations
(Bachelard et al., 1973; Cunningham, 1986; Gjedde and
Diemer, 1985; Mason et al., 1992; Pardridge, 1984).
From the formulation of the Michaelis–Menten kinetics,
it is clear that when brain glucose concentrations are
comparable with the measured Kt of glucose transport, a
substantial fraction of the ablumenal side of the glucose
transporter (“enzyme”) must be bound to brain glucose
(“product”). Binding of glucose at the ablumenal mem-
brane is expected to decrease the affinity for glucose
transport as judged from the properties of the glucose
transporter GLUT-1 present ubiquitously at the blood–
brain barrier (Carruthers and Helgerson, 1991). For this
reason and the additional reasons stated by Gruetter et
al., the reversible Michaelis–Menten model is expected
to describe glucose transport at steady state more reliably
(Gruetter et al., 1998). A general consequence of the
reversible model is a linear relation between brain and
plasma glucose concentrations. The reversible model is
indeed able to provide a more consistent description of
cerebral glucose transport, and the resulting Kt is on
the order of 1 to 3 mmol/L (Cunningham et al., 1986;
Gruetter et al., 1998).
Noninvasive measurements of brain glucose under
physiologic conditions are possible using in vivo nuclear
magnetic resonance (NMR). Glucose signals have been
observed in humans and animals using 1H nuclear mag-
netic resonance spectroscopy (MRS) (Gruetter et al.,
1992b, 1996a, 1998; Inubushi et al., 1993; Keltner et al.,
1998; Pfeuffer et al., 2000; van Zijl et al., 1993) or 13C
MRS (Beckmann et al., 1991; Gruetter et al., 1992a,
1998; Mason et al., 1992). In humans, several localized
measurements of brain glucose transport have been re-
ported (Gruetter et al., 1992a, 1996b, 1998). In animals,
glucose signals from enflurane-anesthetized rats were
quantified based on the postmortem lactate signal (Ma-
son et al., 1992). The significance of the animal study by
Mason et al. may have been limited by the lack of lo-
calization as judged from the detection of intense extra-
cerebral lipid resonances indicating contamination of the
signal from noncerebral sources.
Currently, glucose transport kinetic measurements are
available for rats anesthetized with enflurane or pento-
barbital, but not for those anesthetized with light doses of
-chloralose. The type of anesthetic can affect the cere-
bral glucose concentration because of differential effects
on the cerebral metabolic rate (Archer et al., 1990; Ueki
et al., 1992). It is known that light -chloralose anesthe-
sia preserves functional activation during sensory stimu-
lation, for example, in the somatosensory cortex (Ueki et
al., 1988, 1992). Thus, it has become one of the most
commonly used anesthetics for functional magnetic reso-
nance imaging (fMRI) (Gyngell et al., 1996; Lee et al.,
1999; Mandeville et al., 1997) and 13C isotopic turnover
measurements (Hyder et al., 1996). Therefore, the au-
thors sought to examine the relation between brain and
plasma glucose using the reversible Michaelis–Menten
model in -chloralose anesthetized animals.
It is known that CBF increases with the cerebral meta-
bolic rate of glucose utilization (CMRglc). A marked in-
crease of CBF during acute hypoglycemia in humans and
animals, despite an unchanged or decreased CMRglc, has
been reported (Abdul-Rahman et al., 1980; Della Porta et
al., 1963; Nilsson et al., 1981; Norberg and Siesio, 1976;
Siesjo et al., 1983; Horinaka et al., 1997). However, the
mechanism that triggers these increases in CBF is not
clear to date (Nehlig, 1997) and is most likely different
from that causing changes in CBF because of different
brain activity. How CBF changes are related to brain
glucose concentrations during hypoglycemia has not
been reported in vivo. Therefore, the authors sought to
simultaneously measure glucose transport and CBF to
further understand the regulation of CBF and cerebral
energy metabolism in vivo during hypoglycemia, which
may shed light on what metabolic signal can be respon-
sible for triggering cerebral protection mechanisms.
The purpose of this study was twofold: (1) to deter-
mine whether the reversible Michaelis–Menten kinetics
accurately describe brain glucose transport from hypo-
glycemia to hyperglycemia in the rat, and (2) to deter-
mine the brain glucose concentration at which CBF is
acutely increased during hypoglycemia. Direct measure-
ments of cerebral glucose and global cerebral blood flow
were performed in the -chloralose anesthetized rat brain
using localized NMR methods.
MATERIALS AND METHODS
Animal preparation
The current study was performed according to the guidelines
for the care and use of laboratory animals at the University of
Minnesota and was approved by the Institutional Animal Care
and Use Committee (IACUC). Male Sprague–Dawley rats (n
 24; 262 ± 27 g, mean ± SD) were fasted overnight with
access to water before studies. Animals were anesthetized using
2% isoflurane (Marsam Pharmaceuticals, Cherry Hill, NJ,
U.S.A.) in a 1:1 mixture of nitrous oxide (N2O) and oxygen
(O2) gases for surgery. Animals then were intubated and ven-
tilated with a pressure-driven ventilator (Kent Scientific, Litch-
field, CT, U.S.A.). End-tidal CO2 was monitored with a cap-
nometer (SC-300; BCI International, Waukesha, WI, U.S.A.)
during surgery and experiments.
Catheters were inserted into both femoral arteries for blood
gases and glucose analyzes and monitoring of arterial blood
pressure, and catheters also were inserted into both femoral
veins for intravenous infusion of -chloralose, glucose, and
I.-Y. CHOI ET AL.654
J Cereb Blood Flow Metab, Vol. 21, No. 6, 2001
insulin. Arterial blood pressure, respiratory rate and pattern
were continuously monitored with a multitrace recorder
(AcqKnowledge, Biopak, CA, U.S.A.).
Right after surgery, anesthesia was switched to -chloralose,
which was administered as follows: 40 minutes after a 40
mg/kg bolus injection, a continuous intravenous infusion was
started (24 to 26.7 mg kg−1 h−1). Animals were secured using
a home-built Delrin holder with a bite bar and two ear inserts
to provide a fixed position of the skull. The animal then was
placed in an acrylic holder attached to an insert in the gradient
coil, which ensured stability of the experimental setup for ex-
tended measuring times. Body temperature was maintained at
37.0°C ± 0.5°C with a warm water circulation system based on
a feedback obtained from a rectal temperature probe (Cole
Palmer, Vernon Hills, IL, U.S.A.).
Following a previously described protocol, 99% enriched
[1–13C] D-glucose (20% weight/volume solution; Isotec, Mi-
amisburg, OH, U.S.A.) was infused into the left femoral vein
(Choi et al., 1999). The infusion rate of glucose was continu-
ously adjusted based on the NMR signals of brain glucose and
the concomitantly measured plasma glucose concentrations to
achieve stable target glycemic levels. Measurements were per-
formed after each glucose level had been stable for more than
20 minutes. To induce hypoglycemia, insulin (6 to 10 IU/kg,
Humulin R; Eli Lilly & Co., Indianapolis, IN, U.S.A.) was
infused intravenously for 20 to 50 minutes (Choi et al.,
2000a,c). Arterial blood was withdrawn from the femoral ar-
tery through a Teflon tubing line (Spectrum Chromatography,
Houston, TX, U.S.A.) for blood gas analysis (Pco2, Po2) and
glucose measurements at 25-minute intervals. Blood was im-
mediately centrifuged after sampling, and plasma glucose con-
centrations were measured in a spectrophotometer using a
hexokinase method. The concentration of whole blood glucose
also was measured using a glucose oxidase method (Roche
Diagnostics, Indianapolis, IN, U.S.A.), calibrated against the
plasma glucose measurements. Physiologic parameters were
adjusted and maintained within normal ranges throughout
experiments.
Nuclear magnetic resonance methods
All experiments were performed on a 9.4 Tesla, 31-cm bore
horizontal magnet (Magnex Scientific, Abingdon, U.K.), inter-
faced to an INOVA console (Varian, Palo Alto, CA, U.S.A.).
An actively shielded gradient coil (Magnex Scientific) with an
11-cm inner diameter was used, which was capable of switch-
ing 300 mT/m in 500 microseconds. A quadrature 1H radio-
frequency (RF) coil (14 mm in diameter) and a linear three-turn
13C RF coil (12 mm in diameter) (Adriany and Gruetter, 1997)
were used as a transceiver for 1H MRS and MRI, as well as for
13C MRS, respectively. A 99% 13C-enriched formic acid
sphere was located at the center of the 13C coil as an external
reference, and the coil was placed on the animal’s head as
described previously (Choi et al., 2000b). A butterfly-shaped
RF coil (5 mm in diameter) was built according to Silva et al.
(1995) for arterial spin labeling (see below). The neck coil was
positioned under the neck of the animals, approximately 2 cm
from the center of the brain. Automated, localized shimming
using a fully adiabatic version of FAST(EST)MAP (Gruetter,
1993; Gruetter and Tkac, 2000) was used to adjust the currents
in all first- and second-order shim coils. The field homogeneity
resulted in approximately 20-Hz full width at half maximum of
the in vivo water signal in a nominal ∼500 L volume (8.5 × 6
× 10 mm3, as defined by the pulse sequence parameters). The
nominal volume defined by the RF pulses and the concomitant
gradients is larger than the sensitive volume of the small sur-
face coil because of the rapid fall-off of the RF field along the
small 13C RF coil axis. However, the external reference method
is based on the comparison of identical in vivo and phantom
experiments; thus, potential effects on the quantification of the
signals because of B1 inhomogeneity are minimized (Choi et
al., 1999; Gruetter et al., 1998 and references therein). Three-
dimensional localization based on outer volume saturation was
used to ensure complete elimination of signals from outside of
the volume of interest (VOI) (Choi et al., 2000b). The VOI was
placed in the rat brain to avoid signal contamination from ex-
tracerebral tissues, such as adipose tissue and muscle, which
have been shown to provide contamination to the whole head
signal even when using a small surface coil (Choi et al., 1999).
Quantification of brain glucose signals
13C magnetic resonance spectroscopy. A 99% enriched
[1-13C] D-glucose solution (20% weight/volume solution) was
infused for at least 1.5 hours before the first measurement of
brain glucose was performed. Brain glucose concentrations
were measured after the NMR signals had been stable within
10% for at least 25 minutes. The in vivo 13C NMR signals of
glucose were quantified using the external reference method by
comparison with the measurements of a phantom containing
0.9 mmol/L of 99% enriched [1-13C] D-glucose after calibra-
tion of loading differences and Nuclear Overhauser effects.
Lorentzian fitting using spectrometer software was used to ob-
tain the integral of glucose C1. Glucose concentration in the
brain was calculated based on the following equation (Choi et
al., 1999; Gruetter et al., 1998):
Glc =
IGlc
invivo × IFA
ref × 0.9
IGlc
ref × IFA
invivo , (1)
where IGlc and IFA are the integrals of glucose and the formic
acid signals, respectively, and 0.9 is the 13C glucose concen-
tration in the reference [1-13C] D-glucose phantom. Super-
scripts “ref” and “in vivo” refer to the reference phantom and
the in vivo rat brain, respectively.
1H magnetic resonance spectroscopy. To estimate the 13C
fractional enrichment of plasma glucose, 1H NMR spectra of
plasma samples were obtained using a stimulated echo acqui-
sition mode (STEAM) sequence. Plasma samples were ob-
tained 1 hour after the start of glucose infusion for each animal
and deproteinized using perchloric acid.
In addition, 1H NMR spectra were acquired in three animals
for absolute quantification of brain glucose signals with 12C
glucose infusion. The glucose infusion protocol was identical to
the 13C NMR experiments as described above. Glucose quan-
tification was performed by frequency domain analysis with
LCModel (Pfeuffer et al., 1999) from 150-L volume in the
brain relative to the water signal. A STEAM sequence with a
VAPOR water suppression scheme was used (echo time  2
milliseconds, repetition time  5 seconds, and mixing time 
20 milliseconds) (Tkac et al., 1999).
Determination of glucose transport kinetics
The reversible Michaelis–Menten kinetics of glucose trans-
port assumes that the product formation (that is, the transport of
glucose into the brain or the formation of brain glucose from
plasma glucose) is not unidirectional:
Gplasma + GT↔ GT − Gplasma↔
GT − Gbrain →← Gbrain + GT (2)
Gbrain (mol/g) denotes brain glucose, Gplasma (mmol/L) de-
notes plasma glucose, and GT denotes the glucose transporter
protein at the blood–brain barrier, GLUT-1. Using this model at
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steady state, brain glucose concentrations can be expressed by
the following equation (Gruetter et al., 1998):
Gbrain = Vd 
 TmaxCMRglc − 1  Gplasma − Kt
Tmax
CMRglc
+ 1
. (3)
Because incorporation of multiple membranes in the glucose
entry process does not change the linearity of brain glucose as
a function of plasma glucose, the authors assumed the formu-
lation for a single membrane (Gruetter et al., 1998). Tmax
(mol g−1 min), therefore, denotes the apparent maximal trans-
port rate, Kt (mmol/L) denotes the apparent Michaelis-Menten
kinetic constant, and Vd (0.77 mL/g) denotes the physical dis-
tribution space of glucose in the brain. The model assumes that
the rate-limiting step for glucose transport is at the blood–brain
barrier with a uniform physical distribution of glucose in ex-
tracellular and intracellular spaces (Gjedde, 1992; Gjedde and
Diemer, 1983; Holden et al., 1991; Pfeuffer et al., 2000). From
Eq. 3, it is clear that the reversible Michaelis–Menten model
predicts a linear relation between brain glucose and plasma
glucose in contrast to the standard Michaelis–Menten model,
which predicts an asymptotic upper limit for the brain glucose
concentration (Gruetter et al., 1998).
Glucose transport at steady state described by the reversible
model is depicted schematically in Fig. 1A. The reversible
model assumes that sufficient glucose molecules are present at
the ablumenal membrane and that the glucose molecules bind a
significant fraction of the transporter, as evidenced by brain
glucose concentrations approaching the previously published
Kt of transport (Gruetter et al., 1998). The reversible model
further assumes that glucose bound to one side of the trans-
porter will inhibit glucose transport from the other side of the
membrane, as evidenced by cytochalasin B and maltose bind-
ing studies (Carruthers and Helgerson, 1991; Hamill et al.,
1999). In contrast, the standard model, which is depicted sche-
matically in Fig. 1B, assumes that flux of glucose in either
direction is not affected by the concentration of the transported
glucose. Therefore, this formulation is functionally equivalent
to the assumption that two functionally distinct transporters are
present for import and export of the glucose. To indicate the
difference between the models with respect to the effect of
product inhibition, those glucose molecules that have an effect
on the glucose transport rates are indicated as filled circles in
Fig. 1.
The small blood volume in the rat brain of 3.4 mL/100 g
(Shockley and LaManna, 1988) is expected to result in small
contributions to the total glucose signal. Taking into account
those signal fractions, the kinetic constants decrease by less
than 8%. Therefore, the signal from blood glucose does not
affect the conclusion of the current study and the contribution
of plasma glucose to the total glucose signal was neglected.
Fitting was performed using the Levenberg–Marquardt
FIG. 1. Reversible Michaelis–Menten
kinetics of glucose transport. (A)
Scheme shows a representation of uni-
directional fluxes involved in glucose
transport at steady state (Eq. 3), de-
scribed by the reversible Michaelis–
Menten kinetics. Gplasma (µmol/g) de-
notes the plasma glucose, GT the glu-
cose transporter at the cell membrane,
and Gbrain (µmol/g) the brain glucose.
Transmembrane glucose is assumed
to affect the affinity for cis-membrane
glucose transport (product inhibition).
(B) For comparison, the standard
model is shown schematically. Product
formation for glucose transport in both
directions is assumed to be indepen-
dent of the respective product concen-
tration; thus, this model implicitly as-
sumes that transported glucose has no
effect on the transport mechanisms.
Both models assume a uniform distri-
bution of glucose in the brain’s aque-
ous phase beyond the blood–brain bar-
rier. The cerebral metabolic rate for glu-
cose (CMRglc) is assumed to be
constant. Filled circles indicate glucose
molecules (“substrate” and “product”)
having an effect on the respective uni-
directional transport rates.
I.-Y. CHOI ET AL.656
J Cereb Blood Flow Metab, Vol. 21, No. 6, 2001
algorithm as described previously (Gruetter et al., 1998). Errors
were determined using a Monte Carlo simulation with a 0.7
mol/g root-mean-square noise level, which on average pro-
duced the same sum of residuals squared.
Cerebral blood flow measurement
Cerebral blood flow was measured in seven animals using a
continuous arterial spin labeling method (Silva et al., 1995;
Zhang et al., 1995). Measurements were performed when brain
and plasma glucose levels were stable. A butterfly-shaped RF
coil (5 mm in diameter) was placed under the neck (Silva et al.,
1999). Coronal images (2-mm-thick) located at the center of the
VOI were obtained using echo-planar imaging (EPI). Inplane
resolution was 0.5 × 0.5 mm2, and images were averaged over
24 seconds (8 averages with TR  3 seconds or 4 averages
with TR  6 seconds). To label arterial spins in the carotid
arteries, RF pulses were applied to the neck coil for 3 seconds
at +8.5 kHz relative to the brain water signal with a concomi-
tant 10 mT/m gradient along the z-axis. Control images were
acquired by changing the frequency of the RF irradiation sym-
metrically relative to the water frequency.
Cerebral blood flow maps were calculated according to the
following equation (Silva et al., 1999; Zhang et al., 1995):
CBF =

T1
S0 − ST
ST + 2 − 1S0
, (4)
where  (mL/g) denotes the brain–blood partition coefficient of
water, T1 (s) the longitudinal relaxation time of tissue water, 
is the efficiency of arterial spin labeling, and So and ST are
signal intensities of control and arterial spin labeled images,
respectively. The values used for the CBF calculation were  of
0.9 mL/g (Herscovitch and Raichle, 1985) and T1 of 1.9 sec-
onds (Tsekos et al., 1998). In the current study, it was verified
that  was in agreement with the value of 0.81 (Silva et al.,
1999 and references therein). The average value of CBF was
calculated for an 8.5 × 6 mm2 region of interest. Continuous
arterial spin labeling generally results in magnetization transfer
(MT) from bound macromolecules to the free water signal
within the sensitive volume of the tagging coil. This MT effect
can be neglected if the RF field of the tagging and detection
coils does not couple (Silva et al., 1999). However, in the
current study, coupling was not negligible, resulting in RF be-
ing transferred from the tagging coil to the quadrature detection
coil and concomitant MT effects (Pekar et al., 1996). There-
fore, arterial spin labeling experiments were performed on each
rat postmortem, where blood flow is zero, using identical meth-
ods as in the in vivo experiments. The postmortem signal dif-
ference (So − ST) was subtracted from each CBF measurement
and incorporation of this correction term reduced interindivid-
ual scatter of CBF values.
RESULTS
All brain glucose measurements (n  24) were per-
formed after glucose levels had been stable for more than
20 minutes. The physiologic parameters such as PCO2,
PO2, pH, end-tidal CO2, and body temperature were well
within the normal range for each measurement and are
shown in Table 1 for four different levels of plasma
glucose—hypoglycemia, mild hypoglycemia, euglyce-
mia, and hyperglycemia. 13C NMR spectra were ob-
tained with a 2.7-minute temporal resolution throughout
the experiment. To eliminate any noncerebral signal con-
tamination from outside the VOI, a three-dimensional
localization method was used (Choi et al., 2000b). The
choice of gradient strengths and RF bandwidths resulted
in a nominal VOI of ∼500 L, however, the sensitive
volume of the surface coil (12 mm in diameter) actually
results in a much smaller effective sensitive volume. The
correlation between brain glucose and plasma glucose
concentrations is clearly shown in the 13C NMR spectra
in Fig. 2A. The spectra in Fig. 2A are from one animal,
and quantification of brain glucose resulted in 0.1 (bot-
tom), 3.4 (middle), and 7.9 (top) mol/g with corre-
sponding plasma glucose concentrations of 2.4, 11, and
26 mmol/L, respectively. During prolonged [1-13C] glu-
cose infusion, the brain glycogen signal was clearly ob-
servable at 100.6 ppm (Fig. 2A middle trace).
1H NMR spectra of several plasma samples (50 L
each) were acquired to verify that the 13C fractional
enrichment of plasma glucose was close to that of
the infusate (99%). The 1H signals of 13C1 -glucose
were observable at 5.44 and 5.02 ppm, but the signal
at 5.23 ppm attributed to 12C H1 -glucose was close
to the noise level (Fig. 2B). This indicates that the
13C fractional enrichment of C1 proton glucose was close
to 99%.
The brain glucose concentration was a linear function
of the plasma glucose concentration in the range from 4.5
to 30 mmol/L (Fig. 3A). Second-order polynomial fitting
(y  a + bx + cx2) to the data resulted in c  −0.003 ±
0.002, indicating that curvature was not significant in the
data, further verified by visual inspection of the residuals
(not shown). The linear relationship between plasma and
TABLE 1. Physiologic parameters
Plasma Glc
range (mmol/L)
<2
(n  7)
2 to 4.5
(n  8)
4.5 to 10
(n  10)
>10
(n  9)
Plasma Glc (mmol/L) 1.2 ± 0.5 3.3 ± 0.8 6.4 ± 1.8 15.0 ± 3.5
Brain Glc (mol/g) 0.0 ± 0.1 0.5 ± 0.3 (7)* 1.7 ± 0.9 (8)* 4.4 ± 1.2
PCO2 (mm Hg) 39.7 ± 0.7 40.8 ± 2.0 40.0 ± 0.7 39.3 ± 2.1
PO2 (mm Hg) 182.6 ± 5.5 182.6 ± 21.4 187.5 ± 13.1 184.5 ± 10.1
pH 7.40 ± 0.01 7.39 ± 0.02 7.40 ± 0.02 7.41 ± 0.02
CBF (mL 100 g−1 min−1) 119 ± 18.7 75.6 ± 4.0 70.6 ± 6.1 72.8 ± 6.5
Values are given as mean ± SD. Glc, glucose; CBF, cerebral blood flow.
* Number of measurements is shown in parentheses.
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brain glucose is a consequence of using the reversible
Michaelis–Menten model of glucose transport to de-
scribe glucose content (Gruetter et al., 1998). The cor-
responding Eq. 3 was, therefore, used to fit the model to
the data measured at plasma glucose concentrations
greater than 4.5 mmol/L, which is indicated by the solid
line in Fig. 3A. The best fit to the data resulted in an
apparent Michaelis–Menten constant Kt of 3.3 ± 1.0
mmol/L, and the ratio of the maximal transport rate rela-
tive to CMRglc, Tmax/CMRglc, was 2.7 ± 0.13.
The solid straight line in Fig. 3B is identical to the fit
of the reversible Michaelis–Menten model (also shown
as a straight line in Fig. 3A) and was back-extrapolated
to plasma glucose concentrations less than 4.5 mmol/L
(hypoglycemia). This line was in excellent agreement
with experimental measurements (Fig. 3B). 1H MRS
measurements (Fig. 3B, open circles) show excellent
agreement with 13C MRS measurements (Fig. 3B, solid
squares), further supporting the reliability of the quanti-
fication by 13C MRS. At a plasma glucose concentration
of 2.1 ± 0.6 mmol/L, brain glucose concentrations ap-
proached the Km of hexokinase, ∼0.05 mol/g (Mc-
Ilwain and Bachelard, 1985). When the plasma glucose
level was less than 2 mmol/L, the brain glucose concen-
tration was on average 0.0 ± 0.1 mol/g (Table 1, n 
7), which is consistent with the inability to detect NMR
signals at these plasma glucose concentrations, as shown
in Fig. 2A.
In seven animals, the authors simultaneously mea-
sured CBF using perfusion MRI. CBF-weighted images
of the rat brain during mild hyperglycemia (left) and
hypoglycemia (right) are shown in Fig. 4A, and the cor-
responding concentrations of plasma glucose were 12
mmol/L (left) and 1 mmol/L (right), respectively. These
images were proportional to CBF and showed a signifi-
cant increase in image intensity during hypoglycemia.
Corresponding CBF values were 75 (left) and 146 mL
100 g−1 min−1 (right) (Fig. 4A). Above 2 mmol/L plasma
glucose, CBF was 73 ± 6 mL 100 g−1 min−1 (Fig. 4B,
open triangles) and no trend with plasma glucose was
observed (P > 0.77 using regression analysis), nor was
there a substantial variation of Pco2 during these mea-
surements (Table 1).
When the plasma glucose level dreased to less than 2.1
mmol/L, a sharp increase in CBF above the 95% confi-
dence interval of the normal CBF value was observed,
which is indicated by the shaded area in Fig. 4B. Back-
extrapolation of the reversible Michaelis–Menten model
to zero brain glucose was in excellent agreement with the
plasma glucose concentration, at which CBF sharply in-
creased. The average increase in CBF was 57% ± 22%
(P < 0.001) (Table 1).
FIG. 2. 13C and 1H MRS of 13C-labeled glucose in the brain and plasma. (A) The three-dimensional localized 13C NMR spectra of the
rat brain shows the glucose and glycogen region with -glucose (92.96 ppm) and -glucose (96.80 ppm) signals at different concentra-
tions in the brain of ∼0.1 µmol/g (bottom), 3.4 µmol/g (middle), and 7.9 µmol/g (top). Spectra are shown in the stack plot without baseline
correction (LB = 20 Hz). Corresponding plasma concentrations were 2.4 mmol/L (bottom), 11 mmol/L (middle), and 26 mmol/L (top),
respectively. Brain glycogen C1 resonance is discernible at 100.6 ppm. (B) A representative 1H spectrum of deproteinized plasma shows
the H1 resonances coupled to 13C glucose at 5.44 and 5.02 ppm (indicated by the bracket). The 12C1 proton resonance of plasma glucose
at 5.23 ppm is near the noise level, which indicates that the 13C fractional enrichment of C1 glucose in the blood is almost the same as
that of the infusate. The spectrum was acquired in 32 minutes from 54 µL plasma using a STEAM sequence (8 scans, 4 seconds repetition
time). Processing consisted of 1 Hz exponential multiplication, zero filling, FFT and zero-order phase correction. No baseline correction
was applied. The blood sample was taken 1 hour after the start of the [1-13C] glucose infusion and the plasma glucose concentration was
10.5 mmol/L.
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DISCUSSION
This is the first study to directly quantify cerebral
glucose concentrations in the -chloralose anesthetized
rat brain in vivo over a large range of plasma glucose
concentrations (from hyperglycemia extending to severe
hypoglycemia) with concomitant measurements of CBF.
This study confirms that the reversible model provides
an apparent Michaelis–Menten constant of glucose trans-
port (Kt  3.3 ± 1.0 mmol/L) that is identical to previous
studies (for example, Kt on the order of 1 to 3 mmol/L)
within experimental errors (Gruetter et al., 1998). The
result implies that the kinetics of glucose transport across
the blood–brain barrier in rats is similar to that in humans
(Gruetter et al., 1998).
Using the three-dimensional localization method for
13C MRS and the external reference method, a highly
reliable quantification of brain glucose was achieved.
The 13C MRS quantification was further underlined by
the excellent agreement with the localized 1H MRS
quantification (Fig. 3B). Therefore, quantification errors
are most unlikely and if present, they are expected to be
multiplicative and thus independent of the concentrations
of plasma glucose. When using a surface coil as the only
means to localize the signals, noncerebral glucose can
interfere with the measurements even when performed
using a small surface coil (Choi et al., 1999).
A comparison of the kinetic constants (Kt) for brain
glucose transport in Table 2 indicates that the reversible
model provides highly consistent Kt values spanning a
2.7 mmol/L range, and all reported values are identical
within experimental error (top three rows in Table 2).
Whereas, when using the standard model (bottom five
rows in Table 2), Kt spans a range of 9 mmol/L, which
exceeds the reported errors by more than threefold. It is
interesting to note that all Kt obtained with the reversible
model (indicated by the scheme in Fig. 1A) are less than
than the lowest Kt obtained with the standard model
(indicated by the scheme in Fig. 1B). The lower Kt re-
sulting from the reversible model implies that a more
efficient transport system is present at the blood–brain
barrier than is implied by the standard model. For ex-
ample, a high Kt requires a greater density of transporters
for a given Tmax per transporter molecule to achieve the
same glucose transport capacity. Moreover, the current
data show that the kinetic parameters of the reversible
model correctly predict the level of brain and plasma
glucose at which glucose transport becomes rate limiting
for metabolism (Fig. 4B).
The authors recently have provided extensive argu-
ments in support of the reversible model being a more
consistent and adequate description of glucose transport
across the blood–brain barrier (Gruetter et al., 1998).
One of the features of the reversible model is the linear
relation between brain and plasma glucose at steady
state, whereas the standard Michealis–Menten kinetic
formulation generally implies an asymptotic upper limit
for the brain glucose concentration. A near linear relation
is nevertheless possible within the standard model when
assuming that Tmax >> CMRglc. In this case, brain glu-
cose concentrations must approach those in plasma, a
condition that is clearly not present in the brain. On the
other hand, near linear behavior is observed when
Kt/Gplasma is large. Therefore, the authors’ observation of
a linear relation between brain and plasma glucose up to
30 mmol/L plasma glucose implies a high Kt when mea-
sured in the context of standard Michaelis–Menten
FIG. 3. Linear relation between brain and plasma glucose con-
centration. (A) The concentration of brain glucose measured by
13C NMR is plotted as a function of plasma glucose concentration
(solid circles). Solid line shows the best fit of the reversible Mi-
chaelis–Menten model of glucose transport, that is, Eq. 3, to the
data points measured at plasma glucose concentrations greater
than 4.5 mmol/L. Kinetic parameters of the resulting fit are Kt =
3.3 ± 1.0 mmol/L and Tmax/CMRglc = 2.7 ± 0.1 as shown in the
first row in Table 2. (B) Expanded region from A (1 to 13 mmol/L
plasma glucose) covering hypoglycemia and comparing 13C
NMR measurements (solid squares) with 1H NMR measure-
ments (open circles). Solid squares were averaged over 0.5-
mmol/L intervals in plasma glucose (each data point correspond-
ing to 6 to 11 measurements). Solid straight line is identical to the
solid line in A.
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kinetics. Indeed, it was found that fitting the standard
Michaelis–Menten model to the measured brain glu-
cose concentrations, measured as a function of plasma
glucose, yielded a Kt of 11.8 ± 1.6 mmol/L and
Tmax/CMRglc of 4.7 ± 0.14. This Kt is approximately an
order of magnitude greater than the Km reported for
GLUT-1 and for erythrocyte systems in zero-trans and
zero-cis experiments (Carruthers, 1990; Kasahara and
Kasahara, 1996; Vannucci et al., 1997). (Note that the Kt
in the reversible Michaelis–Menten kinetic model is
FIG. 4. Cerebral blood flow (CBF)-
weighted MRI during mild hyperglyce-
mia and hypoglycemia. (A) CBF-
weighted images of the rat brain are
shown during mild hyperglycemia
(left) and during hypoglycemia (right).
Concentrations of plasma glucose
were 12 mmol/L (left) and 1 mmol/L
(right). The difference images were
obtained by subtracting arterial spin
labeled images from control images.
Images were averaged over 24 sec-
onds each to improve signal-to-noise
ratio. CBF was calculated from a
∼100-µL volume. Corresponding CBF
values of the difference images were
75 mL 100 g−1 min−1 (left) and 146
mL 100 g−1 min−1 (right), which are
proportional to the intensity of image
brightness. (B) Seven open squares
show averaged data points of 55
measurements of brain glucose (right
axis) during hypoglycemia, with a
range of plasma glucose concentra-
tion from 0.2 to 4.5 mmol/L. Solid line
is the best fit of the reversible Micha-
elis–Menten model of glucose trans-
port, identical to the solid line in Fig.
3. CBF values (left axis) are shown in
open triangles (n = 7 rats). Shaded
area indicates the 95% confidence in-
terval of normal CBF (mean ± 2 SD).
The x-intercept of the glucose trans-
port fit (solid line) is indicated by the
vertical dotted line, which is where
brain glucose concentrations ap-
proach zero and CBF significantly in-
creases.
TABLE 2. Overview of cerebral glucose transport kinetic constants
Model Method Kt (mmol/L) Tmax/CMRglc Subject (anesthesia)
Reversible MM NMR 3.3 ± 1.0 2.7 ± 0.1 Rat (-chloralose)*
NMR 0.6 ± 2.0 2.3 ± 0.2 Human (none)†
Radioisotope 1.9 ± 0.8 3 Rat (pentobarbital)‡
Standard MM 13C NMR 13.9 ± 2.7 5.8 ± 0.8 Rat (enflurane)§
13C NMR 11.8 ± 1.6 4.7 ± 0.1 Rat (-chloralose)*
Radioisotope 8.0 NA Rat (conscious)¶
Radioisotope (11) 4.9 to 11# (0.52 to 6.7)** Rat (pentobarbital)§
Radioisotope (4) 5.9 to 9.0# (1.9 to 4.1)** Rat (others)§
CMRglc, cerebral metabolic rate of glucose utilization; MM, Michaelis–Menten; NMR,
nuclear magnetic resonance.
* Current study.
† Gruetter et al., 1998.
‡ Cunningham et al., 1986.
§ Taken from Table 3 in Mason et al., 1992 (and references therein).
¶ Holden et al., 1991.
 Number of studies is shown in parentheses.
# Range of Kt is given.
** Range of Tmax (mol g−1 min−1) was reported without CMRglc.
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equivalent to the Km measured using the standard model
in the absence of product, that is, the zero-trans and
zero-cis experiments.)
The kinetic constants afforded by the reversible Mi-
chaelis–Menten model imply that glucose transport
across the blood–brain barrier can fully support sustained
increases in glucose metabolism approximately two-
thirds greater than the basal consumption rate at 5
mmol/L plasma glucose concentration (euglycemia), cal-
culated from the maximally possible unidirectional trans-
port rate, Tin*, into the brain:
T*in = Tmax
Gplasma
Kt + Gplasma
(5)
This value is generally greater than that predicted by
the constants of the standard model. However, glucose
metabolism alone cannot fully explain the increase of
CMRglc during prolonged functional activation studies
such as the 240% increase reported in the -chloralose
anesthetized rat (Hyder et al., 1996). To support such an
increase in metabolism, substrates other than glucose
must be used—for example, endogenous sources such as
brain glycogen, which can be detected by NMR (Choi et
al., 1999). Increased use of brain glycogen during sen-
sory stimulation and hypoglycemia has been reported
(Choi et al., 2000a; Swanson et al., 1992).
When glucose transport becomes rate limiting for me-
tabolism, that is, when brain glucose concentrations ap-
proach zero, CBF increases significantly (Fig. 4B). Ce-
rebral blood flow increases during hypoglycemia have
been reported in several studies (Abdul-Rahman et al.,
1980; Bryan et al., 1987; Della Porta et al., 1963;
Norberg and Siesio, 1976), and the velocity of the
blood in the sagittal sinus increased by 80% at a whole
blood glucose concentration less than 20 mg/dL in the
rat brain anesthetized with halothane (Ogawa et al.,
1990). The authors’ observation that the glucose con-
centration of ∼18 mg/dL in whole blood is the critical
point where CBF increases is consistent with these stud-
ies. As shown in Fig. 4B, back-extrapolation of the
model fit to zero (Gplasma ∼2 mmol/L) predicts the point
at which CBF increased sharply above the 95% confi-
dence interval.
Therefore, the current data provide direct in vivo evi-
dence that the plasma glucose concentration of 2 mmol/L
is the point in which brain glucose approaches zero, sug-
gesting that the rate-limitation of metabolism by glucose
transport appears to be the signal that triggers cerebral
defense mechanisms, possibly directly controlled by
brain glucose. The increase in CBF during hypoglycemia
can be considered neuroprotective because it represents
an attempt to increase capillary glucose concentration
for improved glucose supply to the brain when circulat-
ing glucose levels are decreased below a critical level
(Abdul-Rahman and Siesjo, 1980; Bryan et al., 1986,
1987). The current study suggests that this critical level
is defined by the brain glucose concentration approach-
ing zero.
Conclusions
The authors conclude that the reversible Michaelis–
Menten model of glucose transport provides consistent
kinetic parameters of glucose transport across different
species and during hypoglycemia. The authors propose
that brain glucose is the signal that triggers defense
mechanisms (for example, CBF increases and glycogen
utilization) aimed at improving glucose delivery to the
brain during hypoglycemia.
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